Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia Active Not Recruiting Phase 2 Trials for Ponatinib (DB08901)

IndicationStatusPhase
DBCOND0114145 (Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01746836Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or NilotinibTreatment